Please ensure Javascript is enabled for purposes of website accessibility

Cronos Group to Restate 2019 Financials

By David Jagielski - Mar 18, 2020 at 3:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cannabis company needs to adjust earnings reports from three quarters.

Cronos Group (CRON -6.21%) management announced on Tuesday that they will be restating items from the first three quarters of the cannabis company's fiscal 2019. In a press release, they stated that those quarterly reports "should no longer be relied upon." 

The recommendation to restate the financials comes from the company's Audit Committee and its accounting firm, KPMG. The Audit Committee has been reviewing sales and purchases that took place during the quarters, and it will eliminate some transactions related to bulk resin purchases as well as certain wholesale product sales.

One consequence of the restatement is that it will reduce Cronos's  revenue figures. For the period ending March 31, 2019, the company says 2.5 million Canadian dollars will come off its top line, which had totaled C$6.5 million. And for the period ending Sept. 30, 2019, Cronos will remove CA$5.1 million in revenue. During that period, the company had recorded sales of CA$12.7 million after excise taxes. 

Auditor reviewing financial report.

Image source: Getty Images.

Cronos shares are down close to 75% in one year

Cronos has struggled over the past year, and its underwhelming financial results have been reflected in its stock price. It has also faced headwinds as a result of its exposure to the vaping niche. The Centers for Disease Control and Prevention (CDC) says that more than 2,800 people have suffered lung injuries caused by vaping. Vape sales were supposed to be key to the Cronos's long-term growth, but given the health-related concerns, as well as the fact that the company's key investor, Altria Group (MO -1.92%) has already made multiple writedowns of its investment in vape company Juul, the value of that market segment for Cronos remains a big question mark.

However, the pot stock's decline over the past year still isn't quite as bad as the decline of the Horizons Marijuana Life Sciences ETF (HMLSF -4.39%), which tracks the broader cannabis industry. That ETF is down 79%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
$3.32 (-6.21%) $0.22
Altria Group, Inc. Stock Quote
Altria Group, Inc.
$53.20 (-1.92%) $-1.04
Horizons Marijuana Life Sciences Index ETF Stock Quote
Horizons Marijuana Life Sciences Index ETF
$3.39 (-4.39%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.